+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Michelson Prizes: Next Generation Grants

Michelson Medical Research Foundation

The Michelson Medical Research Foundation (MMRF) established the Michelson Prizes: Next Generation Grants (Michelson Prizes) in 2017 to support early-career investigators using disruptive research concepts and inventive processes to significantly advance the discovery of vaccines and immunotherapies for major global diseases. MMRF is collaborating with Next Frontier Advisors (NFA), a scientific consulting firm, to administer the Prizes.

The Michelson Prizes are looking for applications related to Human Immunology and Vaccine Research. We are interested in research that aims to tackle the current roadblocks in human vaccine development and expand our understanding of immune processes fundamental to successful vaccine and immunotherapy development. Research with potential applications across multiple disease areas and states is of particular interest.

The Michelson Prizes are intended to support individuals early in their careers who possess novel ideas and who have significant potential to execute these ideas to affect transformative change in their respective fields. Research incorporating multiplexed and non-traditional approaches from outside the fields of immunology and vaccinology and demonstrating a high degree of novelty and creative thinking is encouraged. The successful applicants will clearly articulate a vision that challenges current dogma and demonstrate an ability to look beyond convention to make a lasting impact on vaccine and immunotherapy research.

The Michelson Prizes seek to draw young investigators from a wide range of disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, nanotechnology, microbiome, tropical medicine, environmental health, etc.

Applicants must submit a 2-page description of their research proposal, which will be judged with an emphasis on innovation and the ability to bring new insight and approaches to immunology and vaccinebased research. Short-listed candidates will be invited to submit supplemental information to support the selection committee’s final decision-making.

KEY DATES

• Application portal opens: March 30, 2026

• Applications due: June 22, 2026, 11:59 pm EDT (UTC -4)

• Short-listed applicants notified: September 2026

• Supplementary information due: October 2026 (exact date to be communicated)

• Notice of award: December 2026

• Grant cycle: January 1 -- December 31, 2027

AI Based Application Success Predictor

1. Highly innovative and disruptive science

The strongest applications consistently feature:

unconventional ideas,
high-risk/high-reward concepts,
disruptive technologies,
breakthrough immunology,
transformative therapeutic strategies.

MMRF explicitly states that awards are judged on “innovation and potential impact.”

2. Strong focus on human immunology and vaccine science

The most competitive projects directly address:

human immunology,
vaccine discovery,
immunotherapy,
immune-cell engineering,
cancer immunology,
infectious diseases,
immune modulation.

The Michelson Prizes specifically target “human immunology and vaccine development.”

3. Clear translational and therapeutic impact

Successful proposals usually demonstrate potential to:

accelerate vaccine development,
improve immunotherapies,
overcome major immune-system bottlenecks,
create clinically actionable discoveries,
improve treatment precision.

Applications with realistic therapeutic pathways tend to score highly.

4. High-risk/high-reward profile

A distinctive MMRF predictor is willingness to support:

bold exploratory science,
unproven concepts,
frontier technologies,
projects unlikely to receive conventional funding.

A prior winner described the program as supporting projects “that hadn't been done before.”

5. Strong mechanistic and technical sophistication

Competitive applications often involve:

synthetic biology,
CRISPR engineering,
AI/ML,
computational immunology,
protein engineering,
systems immunology,
advanced genomics,
single-cell technologies.

MMRF explicitly encourages applications from AI, computer science, protein engineering, nanotechnology, and related disciplines.

6. Strong early-career investigator trajectory

The Michelson Prizes specifically prioritize:

investigators aged 35 or younger,
postdoctoral fellows,
junior faculty,
physician-scientists,
trainees with exceptional innovation potential.

Strong scientific trajectory is one of the clearest predictors of competitiveness.

7. Strong preliminary or proof-of-concept rationale

Although disruptive ideas are encouraged, successful applications usually still demonstrate:

feasibility evidence,
pilot immunology data,
mechanistic rationale,
proof-of-concept experiments,
translational plausibility.

Reviewer confidence increases substantially when high-risk ideas remain technically credible.

8. Cross-disciplinary integration

High-scoring projects frequently combine:

immunology,
engineering,
AI/data science,
systems biology,
molecular biology,
translational medicine,
computational biology.

Cross-disciplinary convergence is heavily emphasized across Michelson initiatives.

9. Potential to solve major “roadblocks”

MMRF explicitly prioritizes projects addressing:

barriers to vaccine development,
limitations in immune understanding,
translational bottlenecks,
difficult global diseases,
precision immunotherapy challenges.

Applications solving fundamental bottlenecks are especially competitive.

10. Potential for scalable future impact

Reviewers strongly favor projects likely to:

generate major NIH/foundation funding,
launch translational platforms,
create first-in-class therapies,
establish new immunologic paradigms,
support future clinical development.

MMRF funding is often intended as catalytic “innovation acceleration” support.

Common Reasons for Rejection

Frequent reviewer concerns include:

insufficient innovation,
incremental science,
weak translational significance,
poor mechanistic rationale,
inadequate feasibility,
lack of immunology relevance,
unclear therapeutic impact,
overly descriptive research.

Specialties

Public Health

Eligibility Requirements

Applicants must be born on or after January 1, 1990. Early-career investigators, postdoctoral fellows, clinical fellows (including residents and interns), doctoral students and other researchers currently in training positions are eligible for these awards. International applicants are encouraged. Regardless of ethnicity, nationality or citizenship status, an eligible applicant must be employed by or affiliated with an eligible organization. Examples of eligible organizations include academia, biotechnology companies, foundations, government and non-governmental organizations, and research institutes. Individuals from organizations based outside of the US are eligible to apply.

While the Michelson Prizes are focused on research outcomes in the field of vaccine and immunotherapy discovery, applicants from the full spectrum of related disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, nanotechnology, microbiome, tropical medicine, environmental health etc., are encouraged to apply. Prior experience in human immunology and vaccinology is not required; however, the application must clearly articulate how the proposed research will impact and advance our understanding of human immunology and/or vaccine science

Sponsor Details

Sponsor Institute/Organizations: Michelson Medical Research Foundation

Sponsor Type: Corporate/Non-Profit

Address: 11755 Wilshire Blvd, Suite 1400 Los Angeles, CA 90025

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity